XTalks

JANUARY 5, 2021

This year will see the rolling out of much-awaited pandemic-ending COVID-19 vaccines. The pandemic is expected to continue well into 2021 amidst the delivery and distribution of COVID-19 vaccines worldwide. Lockdowns and closures will continue to have staged implementations as the vaccines are phased in.

Life Science 98

Life Science Clinical Trials Clinical Trials Trials 98

XTalks

OCTOBER 12, 2021

Last week, a study that “stumbled upon” a vaccine for rheumatoid arthritis (RA) was published in the Proceedings of the National Academy of Sciences. The vaccine was tested in rats and showed strong, immediate and long-lasting immune responses to confer protection against the disease. With the finding that 14-3-3?

Vaccine 105

Vaccine Vaccination Research Immune Response 105

pharmaphorum

JULY 20, 2021

The EMA has kicked off a rolling review of a COVID-19 vaccine from Sanofi and GlaxoSmithKline, which started a 35,000-patient phase 3 trial in May. So far the EU has approved four COVID-19 vaccines – two mRNA shots from Pfizer/BioNTech and Moderna, and two based on adenoviral vectors from AstraZeneca and Johnson & Johnson.

Vaccination 98

Vaccination Vaccine Protein Immune Response 98

XTalks

NOVEMBER 23, 2021

Canadian pharma and biotech contract development and manufacturing organization (CDMO) Biovectra has announced plans for building one of the first state-of-the-art mRNA vaccine and biomanufacturing facilities in Canada. Related: Medicago’s Plant-Based COVID-19 Vaccine Enters Human Trials. million, respectively.

Manufacturing 98

Manufacturing Vaccination Vaccine Drugs 98

XTalks

JULY 20, 2022

In this episode, Ayesha discussed the FDA authorization of Novavax’s COVID-19 vaccine, making it the fourth authorized/approved COVID vaccine in the US. It is also the first protein-based COVID-19 vaccine to be authorized in the country. Subscribe to the Xtalks Life Science Podcast to never miss a new episode.

Life Science 52

Life Science Vaccination Vaccine Drugs 52

XTalks

JULY 2, 2021

There have been growing reports of women experiencing changes in their menstrual cycle after receiving a shot of a COVID-19 vaccine. Some women have said they got their periods early following vaccination, or that their periods were unusually heavy and/or painful. Related: Moderna’s COVID-19 Vaccine Effective Against New Variants.

Vaccination 105

Vaccination Vaccine Protein Immune Response 105

XTalks

DECEMBER 20, 2021

The World Health Organization (WHO) has backed Novavax’s COVID-19 vaccine, Covovax (NVX-CoV2373), by granting it an emergency use listing (EUL). The company is awaiting on authorization of its vaccine from regulatory health bodies around the world, including the US Food and Drug Administration (FDA) and Health Canada.

Vaccination 96

Vaccination Vaccine Protein Manufacturing 96

XTalks

FEBRUARY 20, 2024

GlaxoSmithKline’s (GSK) Arexvy and Pfizer’s Abrysvo are the first-ever approved vaccines against respiratory syncytial virus (RSV). The vaccines received approvals from the US Food and Drug Administration (FDA) in May 2023 for the prevention of RSV infection. Arexvy costs $280 per dose while Abrysvo is $295.

Vaccination 105

Vaccination Vaccine Containment Marketing 105

XTalks

JUNE 5, 2023

Pfizer has announced that its respiratory syncytial virus (RSV) vaccine, Abrysvo, has received approval from the US Food and Drug Administration (FDA). Abrysvo, the bivalent RSV prefusion F (RSVpreF) vaccine, is intended for the prevention of lower respiratory tract disease (LRTD) caused by RSV in individuals aged 60 years and older.

Vaccination 98

Vaccination Vaccine FDA Approval Protein 98

XTalks

JUNE 16, 2021

Novavax shared the latest data from its ongoing late-stage COVID-19 vaccine trial, which shows that its yet-to-be authorized shot provides 100 percent protection against moderate and severe disease and has an overall efficacy of 90.4 Related: Latest Data from Novavax COVID-19 Vaccine Trial Involving B.1.351

Vaccination 98

Vaccination Vaccine Protein Trials 98

XTalks

APRIL 26, 2021

After years of disappointing malaria vaccine trials, a malaria shot developed by researchers at the Jenner Institute at the University of Oxford has demonstrated an unprecedentedly high efficacy of 77 percent, and may be the magic bullet the world has been waiting for against the deadly disease.

Vaccination 105

Vaccination Vaccine Immune Response Trials 105

XTalks

NOVEMBER 23, 2020

Adding to recent announcements from Pfizer and Moderna on the efficacy of their COVID-19 vaccine candidates, AstraZeneca and Oxford revealed today that their vaccine contender is 70 percent effective, and could be as high as 90 percent. Oxford-AstraZeneca COVID-19 Vaccine Induces Immune Responses in Early Clinical Trials.

Vaccination 97

Vaccination Vaccine Clinical Trials Clinical Trials 97

XTalks

OCTOBER 26, 2023

The best way to prevent the flu is by getting vaccinated every year. The CDC and the World Health Organization (WHO) recommend annual flu vaccination for most people, especially those at high risk of serious complications, like pregnant women, elderly individuals, children and people with certain chronic health conditions.

Vaccination 105

Vaccination Vaccine RNA Manufacturing 105

XTalks

NOVEMBER 6, 2024

Gelteq’s formulations enable the delivery of various active ingredients like branched-chain amino acids, protein, caffeine and essential minerals, opening applications in sports performance, nutrition and therapeutic use.

Drug Delivery 104

Drug Delivery Drugs Bioequivalency Bioavailability 104

XTalks

MARCH 2, 2021

a pharmaceutical company of Johnson & Johnson, garnered emergency use authorization (EUA) from the US Food and Drug Administration (FDA) for its COVID-19 vaccine candidate (Ad26.COV2.S) S) over the weekend, shortly after evaluation of study data from trials of the vaccine by the agency. Janssen Inc.,

Vaccination 98

Vaccination Vaccine Trials Clinical Trials 98

XTalks

FEBRUARY 29, 2024

Dual-function fusion proteins represent a cutting-edge approach in biopharmaceutical research, offering a promising avenue for the development of novel therapeutics in the treatment of complex diseases such as cancer and autoimmune disorders. At the helm of this venture is Dr. Taylor H. How is your lead program differentiated?

Protein 94

Protein Development Clinical Trials Clinical Trials 94

pharmaphorum

SEPTEMBER 22, 2022

Alexandre Le Vert, CEO and co-founder of Osivax, discusses the company’s breakthrough vaccine technology, oligoDOM, and how it’s driving the development of new influenza and SARS-CoV-2 vaccines that attack T-cells, providing a long-lasting effect. The technology. Antibodies cover the pathogen of the virus and neutralise it.

Vaccination 97

Vaccination Vaccine Antibody Clinical Trials 97

XTalks

DECEMBER 14, 2021

Moderna revealed the first interim results from a small, Phase I study of its mRNA-based influenza vaccine, which showed that the vaccine had no significant safety concerns and elicited immune responses against four strains of the influenza virus. Related: Moderna Unwilling to Share COVID-19 Vaccine Formula Amid Vaccine Inequities.

Vaccination 98

Vaccination Vaccine Immune Response Antibody 98

XTalks

JANUARY 31, 2022

COVID-19 vaccine makers Pfizer/BioNTech and Moderna have both commenced trials for their new variant-specific vaccines targeting omicron. Pfizer and BioNTech have started to enroll participants in a study that will evaluate the new version of their COVID-19 vaccine that targets the omicron variant of SARS-CoV-2.

Vaccination 98

Vaccination Vaccine Trials Antibody 98

XTalks

JULY 20, 2022

million state-of-the-art mRNA vaccine and biomanufacturing facility, making it one of the first in the country. The cutting-edge plant will be dedicated to the manufacturing of mRNA vaccines and therapeutics. Related: Biovectra to Build First mRNA Vaccine and Drug Manufacturing Plant in Canada. Learn more! In addition to a $39.8

Vaccination 105

Vaccination Vaccine Manufacturing Life Science 105

XTalks

JULY 25, 2023

Emergent BioSolutions, a multinational specialty biopharmaceutical company headquartered in Gaithersburg, Maryland, has achieved a significant milestone with the approval of its Cyfendus (Anthrax Vaccine Adsorbed, Adjuvanted) vaccine by the US Food and Drug Administration (FDA). How Does Cyfendus Work? mL for intramuscular injection.

FDA Approval 98

FDA Approval Vaccination Vaccine Antibody 98

Pharmaceutical Technology

MAY 8, 2023

Within the emerging innovation stage, cell therapy for ocular disorders, coronavirus vaccine components, and DNA polymerase compositions are disruptive technologies that are in the early stages of application and should be tracked closely. There are four types of influenza viruses: A, B, C, and D.

Antibody 246

Antibody Vaccination Vaccine Dermatology 246

XTalks

JUNE 20, 2022

Hereditary ATTR has an autosomal dominant pattern of inheritance and is caused by point mutations in the transthyretin ( TTR ) gene that codes for the transthyretin transport protein found in the plasma and cerebrospinal fluid. Alnylam filed lawsuits against both companies in March this year over the alleged patent infringements.

FDA Approval 98

FDA Approval Protein Genetics RNA 98

XTalks

SEPTEMBER 15, 2020

A vaccine developed by Swedish company Diamyd Medical has demonstrated significant treatment efficacy in a predefined genetic subgroup of individuals with type 1 diabetes in a Phase IIb clinical trial. In the trial, the vaccine was injected directly into the lymph nodes of type 1 diabetic individuals.

Vaccine 103

Vaccine Vaccination Insulin Trials 103

XTalks

MAY 10, 2023

In this episode, Ayesha talked about the FDA approval of the world’s first vaccine for respiratory syncytial virus (RSV). The vaccine is approved for adults 60 years of age and older. Read more about the vaccine, including clinical trial results on its efficacy and safety.

Life Science 40

Life Science Vaccination Vaccine FDA Approval 40

XTalks

NOVEMBER 6, 2020

Canadian clinical-stage biotech company Symvivo Corporation has developed an oral COVID-19 vaccine that entered clinical trials this week. The first healthy volunteer was dosed with the vaccine in Australia as part of the bacTRL-Spike COVID-19 Phase I clinical trial. Related: Red Meat Allergy Test Gets FDA Clearance. “We

Clinical Trials 75

Clinical Trials Clinical Trials Vaccination Vaccine 75

Pharmaceutical Technology

APRIL 18, 2023

Within the emerging innovation stage, cell therapy for ocular disorders, coronavirus vaccine components, and DNA polymerase compositions are disruptive technologies that are in the early stages of application and should be tracked closely. These can serve as an important component of a vaccine.

Protein 147

Protein Vaccination Vaccine Production 147

XTalks

MAY 19, 2021

As vaccinations continue to ramp up worldwide in the fight against COVID-19 amidst uncertainties over variants of concern, early data from a lab study shows that the mRNA COVID-19 vaccines from Pfizer and Moderna are effective against some of the variants. 1.117 and South African B.1.351 1.351 variants. 1.117 and South African B.1.351

Vaccination 82

Vaccination Vaccine Protein Immune Response 82

Pharmaceutical Technology

JUNE 4, 2023

Within the emerging innovation stage, cell therapy for ocular disorders, coronavirus vaccine components, and DNA polymerase compositions are disruptive technologies that are in the early stages of application and should be tracked closely. There are two main genes in the AAV genome, rep and cap, which encode nine different proteins.

Gene 262

Gene Gene Therapy Genetics DNA 262

XTalks

FEBRUARY 19, 2024

Moderna has been testing an experimental mRNA vaccine aimed at combating the human cytomegalovirus (CMV), which poses significant health risks to newborns and immunocompromised patients. The team used the data and patient samples from a gB/MF59 Phase II trial in adolescent girls as a benchmark to assess the new mRNA-based vaccine.

Vaccination 59

Vaccination Vaccine Trials Clinical Trials 59

XTalks

JULY 30, 2020

The research provides an even more compelling reason to get vaccinated for those on the fence about the shot’s effectiveness at preventing the seasonal flu. These groups should have the highest vaccination rates because they are the most at risk; however, our findings show the opposite – flu vaccinations are under-utilized,” said Roshni A.

Vaccination 85

Vaccination Vaccine Protein Immune Response 85

Pharmaceutical Technology

NOVEMBER 22, 2022

Vaccines are our number one weapon in the fight against infectious diseases, but their development has historically involved a long and complex process taking up to a decade. Before COVID-19, Merck held the record for the fastest modern vaccine ever developed. mRNA’s potential for rapid vaccine delivery.

Manufacturing 130

Manufacturing Vaccination Vaccine RNA 130

XTalks

SEPTEMBER 8, 2020

The company has signed on to help manufacture AstraZeneca’s COVID-19 vaccine candidate, AZD1222, intended to protect against the SARS-CoV-2 novel coronavirus. AMRI is proud to partner with AstraZeneca in pursuit of a vaccine that could protect people against the coronavirus pandemic,” said John Ratliff, CEO of AMRI, in a statement.

Manufacturing 83

Manufacturing Vaccination Vaccine Allergies 83

XTalks

JUNE 15, 2022

Last week, Novavax announced that it received positive feedback from the US Food and Drug Administration (FDA) Vaccines and Related Biological Products Advisory Committee (VRBPAC) regarding the safety and efficacy of its COVID-9 vaccine (NVX-CoV2373). The Novavax COVID-19 Vaccine Candidate. The vaccine is given in two doses.

Vaccination 59

Vaccination Vaccine Immune Response Protein 59

XTalks

OCTOBER 11, 2024

This study adds significant findings to Arexvy’s profile as the first RSV vaccine to show protection over such an extended period. The trial assessed vaccine efficacy using RSV-LRTD cases, which refer to lower respiratory tract infections caused by RSV, leading to complications like pneumonia. Efficacy over the entire study was 62.9

Vaccination 103

Vaccination Vaccine Immune Response Trials 103

Pharmaceutical Technology

JULY 22, 2022

In addition, immunity against the infection is found to wane for both previously infected individuals and the vaccinated. Kai Kupferschmidt, a science journalist, shared an article on the rising measles cases worldwide. Measles is highly contagious and therefore is more visible when vaccine levels decline, the article noted.

Vaccination 130

Vaccination Vaccine Life Science Immune Response 130

XTalks

NOVEMBER 10, 2020

Update (November 10, 2020): Pfizer and BioNTech announced in a press release yesterday that their candidate COVID-19 vaccine was found to be more than 90 percent effective in preventing infection by the novel coronavirus in Phase III trials. The ongoing Phase III trial continues to evaluate the mRNA vaccine in close to 44,000 individuals.

Vaccination 75

Vaccination Vaccine Trials Clinical Trials 75